Could a tweak to an implanted device ease stomach pain?
NCT ID NCT07556237
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether changing the settings on an already-implanted stomach pacemaker (Enterra™) can reduce chronic abdominal pain in people with gastroparesis, a condition where the stomach empties slowly. Researchers will randomly assign 150 adults to one of three stimulation programs and track their pain, symptoms, and quality of life over 8 weeks. The goal is to find a better way to manage pain without extra medications.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Enterra™ neurostimulator (implanted device)
What this could lead to
If successful, this could provide a new way to manage chronic abdominal pain in people with gastroparesis without adding new drugs.
What could go wrong
This is a small, early-stage study testing different programming settings on an already-approved device. It may not show a clear benefit for pain, and results may not apply to everyone with gastroparesis.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROPARESIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Louisville Clinical Trials Unit
Louisville, Kentucky, 40202, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••